Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study

Retinitis Pigmentosa Clinical Trial

— AMOUR  

Official title:

Prospective Non-randomised Exploratory Study to Assess the Safety and Efficacy of Aflibercept (Eylea) in Cystoid Macular Oedema (CMO) Associated With Retinitis Pigmentosa (RP)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02661711
• Other study ID #: MICM1014
• Secondary ID: 2015-003723-65
• Status: Completed
• Phase: Phase 2
• Start date: March 2016
• Est. completion date: October 2017

Study information

• Verified date: November 2023
• Source: Moorfields Eye Hospital NHS Foundation Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and efficacy of intravitreal injections of Aflibercept (Eylea) in treating Cystoid Macula Oedema (CMO) in patients with underlying Retinitis Pigmentosa (RP).

Description:

This is a 17 month phase II therapeutic exploratory trial in Cystoid Macular Oedema (CMO) with underlying Retinitis Pigmentosa (RP). The study design is a prospective, open-label, interventional non-randomised trial. All patients enrolled in the study will receive intravitreal injections of Aflibercept (Eylea).

There will be a 9 month recruitment window and patient participation will be for 12 months; 30 patients aged 16 years or older presenting in the Medical Retina and Genetics clinics at Moorfields Eye Hospital with Cystoid Macula Oedema (CMO) with underlying Retinitis Pigmentosa (RP) will be approached by the study team to discuss participation in the AMOUR study and be given a patient information leaflet. If patients decide to participate in the study they will be invited to the NIHR Moorfields Clinical Research Facility for a baseline screening where written informed consent will be given by the patient and various assessments will be performed to confirm eligibility.

Patients enrolled in the study will receive intravitreal injections of 2mg of 40mg/ml of Aflibercept (Eylea) solution in the study eye. In the first three months, patients will receive a loading dose of Aflibercept (Eylea) with one injection every four weeks. After the first three months, treatment frequency will follow a treat and extend protocol for up to 12 months from date of study enrolment. Extension from 4 weekly to 6,8,10 and 12 week follow up will occur when there is no further reduction in macula fluid compared to the previous visit. Patients will receive a minimum of 5 injections before being deemed as non-responders to treatment.

Imaging and assessments such as optical coherence tomography imaging, microperimetry and visual acuity will be used to assess response to treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: October 2017
• Est. primary completion date: October 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• CMO in association with RP

• > 16 years of age

• Unilateral or Bilateral CMO (the worse eye only will be treated - defined as the eye with a greater central macular thickness (CMT) on OCT)

• No previous oral treatment for CMO for last 3 months

• No previous peribulbar or intravitreal treatment for CMO in the study eye for last 3 months

• No previous topical treatment for CMO in the study eye for last 1 month

• Central visual impairment that in the view of the Principal Investigator is due to CMO

• BCVA better than 3/60

Exclusion Criteria:

• Insufficient patient cooperation or media clarity to allow adequate fundus imaging.

• Evidence of visually significant vitreo-retinal traction or epiretinal membrane on OCT that in the Principal Investigator's opinion is highly likely to significantly limit the efficacy of intravitreal therapy.

• History of cataract surgery within prior 3 months or cataract surgery anticipated within 6 months of starting the study.

• Any anti-VEGF treatment to study eye within 3 months.

• History of YAG capsulotomy performed within 3 months.

• Uncontrolled Intraocular pressure (IOP) > = 24 mmHg for ocular hypertension (on topical IOP lowering medications)

• Advanced glaucoma (in the opinion of a glaucoma specialist).

• Patients with active or suspected ocular or periocular infections

• Patients with active severe intraocular inflammation.

• Patients with a new, untreated retinal tear or detachment

• Patients with a stage 3 or 4 macular hole

• Thromboembolic event (MI/CVA/Unstable Angina) within 6 months.

• Pregnancy or family planned within 15 months

• Females who are breast feeding

• Known allergy or hypersensitivity to anti-VEGF products

Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 12 weeks after treatment discontinuation. The MHRA advise double contraception.

Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for trial treatment.

Note: Subjects are considered not of child bearing potential if they are surgically sterile (i.e. they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.

Related Conditions & MeSH terms

• Edema
• Macular Edema
• Macular Oedema
• Retinitis
• Retinitis Pigmentosa

Intervention

Drug:
• Aflibercept
2mg of 40mg/ml of Eylea Solution administered via intravitreal injection every four weeks for three months (loading dose), followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow up will occur where there is no reduction in macula oedema compared with the previous visit. Number of cycles; minimum of 5 injections and maximum of 13 injections per study eye.

Locations

Country	Name	City	State
United Kingdom	Moorfields Eye Hospital	London

Sponsors (2)

Lead Sponsor	Collaborator
Moorfields Eye Hospital NHS Foundation Trust	Bayer

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Central Macular Thickness (CMT) on Spectral Domain OCT (SDOCT) at 12 Months	Mean Central Macular Thickness (CMT) on Spectral Domain OCT (SDOCT) at 12 months	at 12 months
Secondary	The Mean Change in Central Macular Thickness on Spectral Domain Optical Coherence Tomography (SD-OCT) From Baseline to 6 Months and Baseline to 12 Months		baseline to 6 months and baseline to 12 months
Secondary	The Mean Best Corrected Visual Acuity (BCVA) Using the ETDRS Visual Acuity Chart at 6 and 12 Months	Mean Best Corrected Visual Acuity (BCVA) using the ETDRS visual acuity chart at 6 and 12 months.; BCVA is the best possible vision an eye can see with corrective lenses, measured using the ETDRS visual acuity chart. The ETDRS score is calculated as the total number of letters correctly read at 4m from the chart plus 30 (if 20 or more letters can be read at 4m).	baseline to 6 months and baseline to 12 months
Secondary	The Mean Change in ETDRS BCVA at 6 Months and at 12 Months	Mean ETDRS BCVA change at 6 months and at 12 months. BCVA is the best possible vision an eye can see with corrective lenses, measured using the ETDRS visual acuity chart. The ETDRS score is calculated as the total number of letters correctly read at 4m from the chart plus 30 (if 20 or more letters can be read at 4m).	at 6 months and at 12 months
Secondary	The Mean Macular Volume on SDOCT at 6 and 12 Months		baseline to 6 months and baseline to 12 months
Secondary	The Mean Change in Macular Volume on SDOCT From Baseline to 6 Months and Baseline to 12 Months		baseline to 6 months and baseline to 12 months
Secondary	Report All Adverse Events and Serious Adverse Events		From date of first injection for first patient to the end of the study (17 months)
Secondary	The Mean Retinal Sensitivity Using Microperimetry at 6 and 12 Months		At 6 months and at 12 months
Secondary	The Mean Change in Retinal Sensitivity Using Microperimetry From Baseline to 6 Months and Baseline to 12 Months		From baseline to 6 months and baseline to 12 months
Secondary	The Mean Number of Intravitreal Injections Administered		17 months (from first patient first visit to last patient last visit)
Secondary	The Mean Central Macular Thickness (CMT) on Spectral Domain OCT (SDOCT) at 6 Months	The Mean Central Macular Thickness (CMT) on Spectral Domain OCT (SDOCT) at 6 Months	at 6 months